1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PDX-017, 2010-022230-81, NCT01420679
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C14012, 2011-003545-18, NCT01482962
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-113, NCT01188876
|
|
4.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: I 169210, NCI-2010-01583, NCT01178944
|
|
5.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PROTOCOL 0761-009, NCT01626664
|
|
6.
|
Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: HEMMYL0014, SU-04282010-5783, NCT01114282
|
|
7.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 19 and over Sponsor: NCI, Other Protocol IDs: 238-10, NCI-2010-02014, NCT01206465
|
|
8.
|
Phase: Phase I Type: Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2011-0916, NCT01532011
|
|
9.
|
Phase: Phase I Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SPI-FUS-12-102, NCT01789723
|